nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—DRD4—Gilles de la Tourette syndrome	0.34	0.407	CbGaD
L-DOPA—DRD3—Gilles de la Tourette syndrome	0.293	0.351	CbGaD
L-DOPA—DRD2—Gilles de la Tourette syndrome	0.203	0.243	CbGaD
L-DOPA—DDC—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.00743	0.0651	CbGpPWpGaD
L-DOPA—L-Histidine—HDC—Gilles de la Tourette syndrome	0.00536	0.791	CrCbGaD
L-DOPA—DRD5—Dopamine receptors—DRD3—Gilles de la Tourette syndrome	0.00532	0.0466	CbGpPWpGaD
L-DOPA—DRD5—Dopamine receptors—DRD4—Gilles de la Tourette syndrome	0.00516	0.0452	CbGpPWpGaD
L-DOPA—DRD5—Dopamine receptors—DRD2—Gilles de la Tourette syndrome	0.00481	0.0421	CbGpPWpGaD
L-DOPA—DRD4—Dopamine receptors—DRD3—Gilles de la Tourette syndrome	0.00392	0.0344	CbGpPWpGaD
L-DOPA—DRD4—Dopamine receptors—DRD2—Gilles de la Tourette syndrome	0.00355	0.0311	CbGpPWpGaD
L-DOPA—DRD1—Dopamine receptors—DRD3—Gilles de la Tourette syndrome	0.00353	0.0309	CbGpPWpGaD
L-DOPA—DRD1—Dopamine receptors—DRD4—Gilles de la Tourette syndrome	0.00343	0.03	CbGpPWpGaD
L-DOPA—DRD3—Dopamine receptors—DRD4—Gilles de la Tourette syndrome	0.00338	0.0296	CbGpPWpGaD
L-DOPA—DRD1—Dopamine receptors—DRD2—Gilles de la Tourette syndrome	0.0032	0.028	CbGpPWpGaD
L-DOPA—PSIP1—midbrain—Gilles de la Tourette syndrome	0.00316	0.0726	CbGeAlD
L-DOPA—DRD3—Dopamine receptors—DRD2—Gilles de la Tourette syndrome	0.00315	0.0276	CbGpPWpGaD
L-DOPA—DRD2—Dopamine receptors—DRD3—Gilles de la Tourette syndrome	0.00267	0.0234	CbGpPWpGaD
L-DOPA—PSIP1—nervous system—Gilles de la Tourette syndrome	0.00259	0.0596	CbGeAlD
L-DOPA—DRD2—Dopamine receptors—DRD4—Gilles de la Tourette syndrome	0.00259	0.0227	CbGpPWpGaD
L-DOPA—PSIP1—central nervous system—Gilles de la Tourette syndrome	0.0025	0.0574	CbGeAlD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.00215	0.0188	CbGpPWpGaD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.00208	0.0182	CbGpPWpGaD
L-DOPA—PSIP1—brain—Gilles de la Tourette syndrome	0.00198	0.0456	CbGeAlD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—DRD2—Gilles de la Tourette syndrome	0.00194	0.017	CbGpPWpGaD
L-DOPA—DDC—midbrain—Gilles de la Tourette syndrome	0.0018	0.0414	CbGeAlD
L-DOPA—SLC7A8—nervous system—Gilles de la Tourette syndrome	0.00171	0.0393	CbGeAlD
L-DOPA—DRD4—brain—Gilles de la Tourette syndrome	0.00165	0.038	CbGeAlD
L-DOPA—SLC7A8—central nervous system—Gilles de la Tourette syndrome	0.00165	0.0378	CbGeAlD
L-DOPA—SLC7A5—midbrain—Gilles de la Tourette syndrome	0.00161	0.0371	CbGeAlD
L-DOPA—DRD3—nervous system—Gilles de la Tourette syndrome	0.00152	0.0349	CbGeAlD
L-DOPA—DDC—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	0.00149	0.013	CbGpPWpGaD
L-DOPA—DDC—nervous system—Gilles de la Tourette syndrome	0.00148	0.034	CbGeAlD
L-DOPA—DRD3—central nervous system—Gilles de la Tourette syndrome	0.00146	0.0336	CbGeAlD
L-DOPA—DDC—central nervous system—Gilles de la Tourette syndrome	0.00142	0.0327	CbGeAlD
L-DOPA—DRD5—nervous system—Gilles de la Tourette syndrome	0.00142	0.0327	CbGeAlD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00138	0.0121	CbGpPWpGaD
L-DOPA—DRD5—central nervous system—Gilles de la Tourette syndrome	0.00137	0.0315	CbGeAlD
L-DOPA—SLC7A5—nervous system—Gilles de la Tourette syndrome	0.00133	0.0305	CbGeAlD
L-DOPA—DRD1—midbrain—Gilles de la Tourette syndrome	0.00132	0.0304	CbGeAlD
L-DOPA—SLC7A8—brain—Gilles de la Tourette syndrome	0.00131	0.03	CbGeAlD
L-DOPA—SLC7A5—central nervous system—Gilles de la Tourette syndrome	0.00128	0.0293	CbGeAlD
L-DOPA—DRD4—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.00125	0.0109	CbGpPWpGaD
L-DOPA—DDC—Parkinsons Disease Pathway—SLC6A3—Gilles de la Tourette syndrome	0.00123	0.0108	CbGpPWpGaD
L-DOPA—DRD5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00118	0.0103	CbGpPWpGaD
L-DOPA—DRD3—brain—Gilles de la Tourette syndrome	0.00116	0.0267	CbGeAlD
L-DOPA—DRD5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00114	0.00999	CbGpPWpGaD
L-DOPA—DDC—brain—Gilles de la Tourette syndrome	0.00113	0.026	CbGeAlD
L-DOPA—DRD4—Nicotine Activity on Dopaminergic Neurons—DRD2—Gilles de la Tourette syndrome	0.00113	0.00986	CbGpPWpGaD
L-DOPA—DRD5—brain—Gilles de la Tourette syndrome	0.00109	0.025	CbGeAlD
L-DOPA—DRD1—nervous system—Gilles de la Tourette syndrome	0.00109	0.025	CbGeAlD
L-DOPA—DRD3—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.00107	0.0094	CbGpPWpGaD
L-DOPA—DRD5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00106	0.00931	CbGpPWpGaD
L-DOPA—DRD1—central nervous system—Gilles de la Tourette syndrome	0.00105	0.0241	CbGeAlD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00102	0.0089	CbGpPWpGaD
L-DOPA—SLC7A5—brain—Gilles de la Tourette syndrome	0.00101	0.0233	CbGeAlD
L-DOPA—DRD3—Nicotine Activity on Dopaminergic Neurons—DRD2—Gilles de la Tourette syndrome	0.001	0.00876	CbGpPWpGaD
L-DOPA—DRD5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000988	0.00865	CbGpPWpGaD
L-DOPA—DDC—Amino acid and derivative metabolism—HDC—Gilles de la Tourette syndrome	0.000983	0.00861	CbGpPWpGaD
L-DOPA—DRD5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000959	0.0084	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000915	0.00802	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000903	0.00791	CbGpPWpGaD
L-DOPA—DRD5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000893	0.00782	CbGpPWpGaD
L-DOPA—DRD4—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000867	0.00759	CbGpPWpGaD
L-DOPA—DRD2—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.000846	0.00741	CbGpPWpGaD
L-DOPA—DRD1—brain—Gilles de la Tourette syndrome	0.000831	0.0191	CbGeAlD
L-DOPA—DRD2—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.000822	0.00719	CbGpPWpGaD
L-DOPA—DRD4—Hypothetical Network for Drug Addiction—DRD2—Gilles de la Tourette syndrome	0.000804	0.00704	CbGpPWpGaD
L-DOPA—DRD4—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000784	0.00687	CbGpPWpGaD
L-DOPA—DRD2—midbrain—Gilles de la Tourette syndrome	0.000781	0.018	CbGeAlD
L-DOPA—DRD1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000781	0.00684	CbGpPWpGaD
L-DOPA—DRD1—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.000777	0.0068	CbGpPWpGaD
L-DOPA—DRD1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000758	0.00664	CbGpPWpGaD
L-DOPA—DRD3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000748	0.00655	CbGpPWpGaD
L-DOPA—DRD5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000744	0.00652	CbGpPWpGaD
L-DOPA—DRD4—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000729	0.00638	CbGpPWpGaD
L-DOPA—DRD1—Hypothetical Network for Drug Addiction—DRD2—Gilles de la Tourette syndrome	0.000724	0.00634	CbGpPWpGaD
L-DOPA—DRD1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000706	0.00618	CbGpPWpGaD
L-DOPA—DRD3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000697	0.0061	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000691	0.00605	CbGpPWpGaD
L-DOPA—DRD4—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000659	0.00577	CbGpPWpGaD
L-DOPA—DRD1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000656	0.00575	CbGpPWpGaD
L-DOPA—DRD2—nervous system—Gilles de la Tourette syndrome	0.000642	0.0148	CbGeAlD
L-DOPA—DRD1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000637	0.00558	CbGpPWpGaD
L-DOPA—DRD3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000629	0.0055	CbGpPWpGaD
L-DOPA—DRD5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000626	0.00548	CbGpPWpGaD
L-DOPA—DRD2—central nervous system—Gilles de la Tourette syndrome	0.000618	0.0142	CbGeAlD
L-DOPA—DRD1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000594	0.0052	CbGpPWpGaD
L-DOPA—DRD2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000589	0.00516	CbGpPWpGaD
L-DOPA—DRD2—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.000587	0.00514	CbGpPWpGaD
L-DOPA—DRD3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000586	0.00513	CbGpPWpGaD
L-DOPA—DRD2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000572	0.00501	CbGpPWpGaD
L-DOPA—DRD4—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000549	0.00481	CbGpPWpGaD
L-DOPA—DRD2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000496	0.00434	CbGpPWpGaD
L-DOPA—DRD1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000495	0.00433	CbGpPWpGaD
L-DOPA—DRD2—brain—Gilles de la Tourette syndrome	0.000491	0.0113	CbGeAlD
L-DOPA—DRD3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000488	0.00427	CbGpPWpGaD
L-DOPA—DRD2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000481	0.00421	CbGpPWpGaD
L-DOPA—DRD4—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000462	0.00404	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000423	0.0037	CbGpPWpGaD
L-DOPA—DRD1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000416	0.00364	CbGpPWpGaD
L-DOPA—DRD3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00041	0.00359	CbGpPWpGaD
L-DOPA—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000386	0.00887	CbGeAlD
L-DOPA—DRD4—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.000385	0.00337	CbGpPWpGaD
L-DOPA—DRD2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000373	0.00327	CbGpPWpGaD
L-DOPA—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000372	0.00854	CbGeAlD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000369	0.00323	CbGpPWpGaD
L-DOPA—Dopamine—DRD4—Gilles de la Tourette syndrome	0.000363	0.0536	CrCbGaD
L-DOPA—DDC—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000352	0.00309	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000342	0.003	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000332	0.00291	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000319	0.00279	CbGpPWpGaD
L-DOPA—DRD2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000314	0.00275	CbGpPWpGaD
L-DOPA—Dopamine—DRD3—Gilles de la Tourette syndrome	0.000313	0.0462	CrCbGaD
L-DOPA—CYP2D6—brain—Gilles de la Tourette syndrome	0.000295	0.00678	CbGeAlD
L-DOPA—Dopamine—SLC6A3—Gilles de la Tourette syndrome	0.000292	0.043	CrCbGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000273	0.00239	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000245	0.00215	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.000244	0.00214	CbGpPWpGaD
L-DOPA—Norepinephrine—DRD2—Gilles de la Tourette syndrome	0.000233	0.0344	CrCbGaD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000227	0.00199	CbGpPWpGaD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00022	0.00193	CbGpPWpGaD
L-DOPA—Dopamine—DRD2—Gilles de la Tourette syndrome	0.000217	0.032	CrCbGaD
L-DOPA—DRD3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.000217	0.0019	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000215	0.00188	CbGpPWpGaD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000205	0.0018	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000204	0.00179	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000194	0.0017	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000191	0.00167	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000189	0.00165	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000188	0.00164	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000185	0.00162	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000184	0.00161	CbGpPWpGaD
L-DOPA—DDC—Metabolism—HDC—Gilles de la Tourette syndrome	0.000181	0.00158	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00018	0.00158	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000179	0.00156	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000176	0.00154	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000176	0.00154	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000167	0.00147	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000166	0.00146	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000164	0.00144	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000163	0.00143	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000156	0.00136	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000151	0.00133	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000151	0.00132	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000148	0.0013	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000146	0.00128	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000145	0.00127	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000144	0.00126	CbGpPWpGaD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000144	0.00126	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000144	0.00126	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000143	0.00126	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000139	0.00122	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000136	0.00119	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000135	0.00118	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000134	0.00118	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000134	0.00117	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00013	0.00114	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000129	0.00113	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000125	0.0011	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000125	0.00109	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000124	0.00108	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000123	0.00108	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000123	0.00107	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000119	0.00104	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000117	0.00102	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000115	0.00101	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000114	0.000996	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00011	0.000967	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000109	0.000956	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000106	0.000928	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	9.88e-05	0.000865	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.83e-05	0.000861	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	9.75e-05	0.000853	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	9.68e-05	0.000848	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.54e-05	0.000836	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.54e-05	0.000836	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	9.46e-05	0.000829	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.42e-05	0.000825	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.42e-05	0.000825	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	9.37e-05	0.000821	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.08e-05	0.000795	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.89e-05	0.000778	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.77e-05	0.000768	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	8.36e-05	0.000732	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.18e-05	0.000716	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.12e-05	0.000711	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.07e-05	0.000706	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.59e-05	0.000665	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.56e-05	0.000662	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	7.42e-05	0.00065	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.37e-05	0.000645	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	7.21e-05	0.000631	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	7.21e-05	0.000631	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.92e-05	0.000606	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.87e-05	0.000601	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.23e-05	0.000545	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	6.17e-05	0.000541	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.17e-05	0.00054	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.14e-05	0.000538	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.6e-05	0.000491	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.58e-05	0.000489	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.56e-05	0.000486	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.39e-05	0.000472	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.32e-05	0.000466	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.3e-05	0.000464	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.07e-05	0.000444	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.04e-05	0.000442	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.02e-05	0.00044	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.96e-05	0.000434	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.9e-05	0.000429	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.83e-05	0.000423	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.81e-05	0.000421	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	4.7e-05	0.000412	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.56e-05	0.000399	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.5e-05	0.000394	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.49e-05	0.000393	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.35e-05	0.000381	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	4.19e-05	0.000367	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	4.15e-05	0.000363	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	4.07e-05	0.000357	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.06e-05	0.000355	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.91e-05	0.000342	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	3.81e-05	0.000334	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	3.7e-05	0.000324	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.55e-05	0.000311	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.52e-05	0.000308	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.47e-05	0.000304	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.31e-05	0.00029	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.2e-05	0.00028	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.15e-05	0.000276	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.99e-05	0.000262	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.98e-05	0.000261	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.89e-05	0.000253	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.85e-05	0.00025	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.84e-05	0.000249	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.7e-05	0.000236	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.66e-05	0.000233	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	2.66e-05	0.000233	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	2.41e-05	0.000211	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.25e-05	0.000197	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.18e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.1e-05	0.000184	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.89e-05	0.000165	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.86e-05	0.000163	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.43e-05	0.000125	CbGpPWpGaD
